Key facts: Fink Seeks AI Funding; BlackRock, Inc. Fagron 2.96%/COSCO 6.95%

BlackRock's crypto ETF assets grew 63% to $79.6 billion, though still 23% below 2025's peak. Institutional interest in Bitcoin and Ethereum ETFs is increasing, with a focus on regulated products. European MiCA regulations provide legal certainty for crypto assets. The growth impacts spot market liquidity but volatility remains moderate.

BlackRock reported $15.49 trillion in AUM as of Sept. 30, equivalent to 47.6% of U.S. annualized GDP. The firm saw $205.466 billion in quarterly net inflows, up slightly from the prior year. Revenue rose 19% to $7.75 billion, with GAAP earnings per share increasing to $10.57. CEO Laurence Fink noted strong client inflows.

Humana (HUM) agreed to a $2.8 bn deal with BlackRock, restructuring ownership of 150 CenterWell clinics. BlackRock acquires WCAS's majority stake, with Humana retaining minority ownership. The deal reduces Humana's balance sheet obligations. Humana's Medicare Advantage star ratings improved, potentially increasing 2028 bonus payments to $4.8 bn, per Evercore ISI. S&P affirmed Humana's BBB rating but maintained a negative outlook.

The SEC issued a warning to major asset managers (BlackRock, State Street, Vanguard) and Climate Action 100+ over their 2021 campaign to replace ExxonMobil board members. The SEC found no violations but expressed concerns about their actions, which some view as an attempt to suppress climate advocacy.

BlackRock reported record $15.49T in AUM, up 15% YoY, with $205.5B in Q3 net inflows. Revenue rose 19% to $7.75B, GAAP EPS up to $10.57. iShares ETFs saw $134.5B in Q3 inflows. AUM equals 47.6% of U.S. Q2 GDP, though not directly comparable.

Humana announced that BlackRock's HPS Investment Partners will acquire Welsh Carson's stake in about 150 CenterWell clinics, valued at $2.8B. The deal, expected to close in Q4 2026, will make BlackRock the majority owner, with CenterWell retaining a minority stake and operational control. Humana stated patient care will remain unchanged, and the deal is not expected to materially affect its 2026 earnings guidance.